Avaliação dos valores sérico e pleural dos marcadores tumorais CEA, CYFRA21-1 e CA 15-3 em portadores de derrame pleural

Wagner, Isabella Coimbra; Guimarães, Murilo José de Barros; Silva, Lilian Karine Neves da; Melo, Francisco Vicente Sales; Muniz, Maria Tereza Cartaxo

doi:10.1590/s1806-37132007000200013

Cited by 18 publications

(51 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…while as Lee et al .,[ 8 ] Dejsomritrutai et al . [ 24 ] and Wagner et al .,[ 31 ] observed sensitivity of 45.2%, 81.5%, and 71.4%, and specificity of 100%, 97%, and 93%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…We observed Serum CEA had a sensitivity of 76.7%, specificity of 94.4%, and accuracy of 83.3% [ Table 6 and Figures 3 – 6 ]. Lee et al .,[ 8 ] Wagner et al .,[ 31 ] and Pasaoglu et al . [ 32 ] observed a sensitivity of 67.6%, 57.1%, and 30.5% specificity of 92.9%, 100% and accuracy of 75%, 93%, and 73%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Sensitivity of CEA is greater and serum CEA concentrations are higher in adenocarcinoma and large cell carcinoma lung. [ 31 ] The normal range of CEA in adult nonsmoker is <6.5 and in smoker <5.0 ng/ml, respectively.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer

Sharma¹,

Bhat²,

Chandel³

et al. 2015

J Carcinog

View full text Add to dashboard Cite

Aims:To assess the diagnostic value of CEA and CYFRA 21-1 (cytokeratin 19 fragments) in serum and pleural fluid in non small cell lung cancer with malignant pleural effusion (MPE).Settings and Design:Two subsets of patients were recruited with lymphocytic exudative effusion, one subset constituted diagnosed patients of NSCLC with malignant pleural effusion and the other subset of constituted with Tubercular pleural effusion.Materials and Methods:CYFRA 21-1 and CEA levels were measured using Electrochemilumiscence Immunoassay (ECLIA). The test principle used the Sandwich method. For both the tests, results are determined via a calibration curve which is instrument specifically generated by 2 - point calibration and a master curve provided via reagent barcode.Statistical Analysis Used:All data are expressed as means ± SD and percentage. All the parametric variables were analysed by student-t test where as non parametric variables were compared by Mann-Whitney U-test Statistical significance was accepted for P values < 0.05. Software used were SPSS 11.5, and MS excel 2007. In order to compare the performance of the tumor markers, receiver operating characteristic (ROC) curves were constructed and compared with area under the curve (AUC). The threshold for each marker was selected based on the best diagnostic efficacy having achieved equilibrium between sensitivity and specificity.Results:In cases serum CYFRA21-1 levels had mean value of 34.1 ± 29.9 with a range of 1.6-128.3 where as in controls serum CYFRA21-1 levels had mean value of 1.9 ± 1.0 with a range of 0.5–4.7. In cases serum CEA levels had mean value of 24.9 ± 47.3 with a range of 1.0, 267.9 where as in controls serum CEA levels had mean value of 1.9 ± 1.4 with a range of 0.2-6.8. The difference in the means of serum CYFRA 21-l (P = 0.000) and CEA (P = 0.046) were statistically significant. In cases pleural fluid CYFRA21-1 levels had mean value of 160.1 ± 177.1 with a range of 5.4–517.2 where as in controls pleural fluid CYFRA21-1 levels had mean value of 15.9 ± 5.7 with a range of 7.2-29.6. In cases CEA pleural fluid levels had mean value of 89.8 ± 207.4 with a range of 1.0–861.2 where as in controls CEA levels had mean value of 2.5 ± 2.3 with a range of 1–8.9. The difference in the means of CYERA 21-1 (P = 0.001) between cases and controls is statistically significant.Conclusions:CYFRA21-1 (serum - pleural fluid) is a sensitive marker for NSCLC with sensitivity of 96.7%, highest of any combination [Serum (CYFRA 21-1 - CEA). CEA (Serum + Pleural Fluid), Pleural Fluid (CYFRA 21-1 + CEA)] and specificity of 77.8%. Levels of CYFRA21-l (serum + pleural fluid) are increased in malignant pleural effusion, so it is better to be used in suspicious malignant pleural effusion showing negative cytology, particularly in the absence of a visible tumor and or unsuitability for invasive procedure.

show abstract

“…while as Lee et al .,[ 8 ] Dejsomritrutai et al . [ 24 ] and Wagner et al .,[ 31 ] observed sensitivity of 45.2%, 81.5%, and 71.4%, and specificity of 100%, 97%, and 93%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer

Sharma¹,

Bhat²,

Chandel³

et al. 2015

J Carcinog

View full text Add to dashboard Cite

show abstract

“…Although CEA has been shown to be specific, sensitivity remains low (<50%) with variable cut-off values precluding routine use. Metastatic breast cancer is another common cause for malignant pleural effusions with CA 15-3 used for both diagnosis and therapeutic monitoring [60]. CYFRA 21-1, a cytokeratin tumour marker has both diagnostic and prognostic roles in nonsmall cell lung cancer [60].…”

Section: The Promise Of Biological Pleural Markers To Determine Thmentioning

confidence: 99%

“…Metastatic breast cancer is another common cause for malignant pleural effusions with CA 15-3 used for both diagnosis and therapeutic monitoring [60]. CYFRA 21-1, a cytokeratin tumour marker has both diagnostic and prognostic roles in nonsmall cell lung cancer [60]. However, due to relatively poor sensitivity for a single test, use of a combination of tumour markers such as CA 125 and CYFRA 21-1 for adenocarcinoma and CEA, CA 15-3, and CYFRA 21-1 for squamous cell cancer of the lung has been recommended.…”

Section: The Promise Of Biological Pleural Markers To Determine Thmentioning

confidence: 99%

Pleural Fluid Analysis: Standstill or a Work in Progress?

et al. 2012

View full text Add to dashboard Cite

Pleural fluid analysis yields important diagnostic information in pleural effusions in combination with clinical history, examination, and radiology. For more than 30 years, the initial and most pragmatic step in this process is to determine whether the fluid is a transudate or an exudate. Light's criteria remain the most robust in separating the transudate-exudate classification which dictates further investigations or management. Recent studies have led to the evaluation and implementation of a number of additional fluid analyses that may improve the diagnostic utility of this method. This paper discusses the current practice and future direction of pleural fluid analysis in determining the aetiology of a pleural effusion. While this has been performed for a few decades, a number of other pleural characteristics are becoming available suggesting that this diagnostic tool is indeed a work in progress.

show abstract

Discovery of Tumor Markers

Cavalcanti

Soares

2021

Advances in Cancer Treatment

View full text Add to dashboard Cite

Avaliação dos valores sérico e pleural dos marcadores tumorais CEA, CYFRA21-1 e CA 15-3 em portadores de derrame pleural

Abstract: The results suggest that these markers might be useful in the differentiation between malignant and benign pleural effusion.

Cited by 18 publications

References 24 publications

Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer

Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer

Pleural Fluid Analysis: Standstill or a Work in Progress?

Discovery of Tumor Markers

Contact Info

Product

Resources

About